Study of VVD-133214 for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests an experimental drug called VVD-133214, alone or with other medicines, in people with advanced solid tumors that have specific DNA repair problems (MSI-H/dMMR). The goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of advanced solid tumor (cancer that has spread or cannot be removed) that is MSI-H or dMMR (a specific DNA repair issue).
- You must have tried standard treatments and either they stopped working or you could not tolerate them.
- You must be well enough to perform daily activities (ECOG performance status 0 or 1).
- You must be able to swallow pills.
- You cannot have certain untreated brain metastases or active infections.
- If you join the group receiving bevacizumab or pembrolizumab, there are extra rules (e.g., no recent major surgery, no autoimmune disease for pembrolizumab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
This study tests a new drug called BMS-986490, either alone or with bevacizumab, for people with advanced solid tumors like colorectal, lung, or stomach cancer that has not responded to standard treatments. The goal is to see if the drug can shrink tumors and help people live longer.
This trial tests a new drug for people with advanced solid tumors that have spread or can't be removed. The drug targets specific proteins on cancer cells to try to shrink or slow the cancer.
This trial tests a new drug combined with a standard treatment for advanced colorectal cancer that has not responded to earlier therapies. It aims to see if the combination can help slow the cancer's growth.
This study is testing an investigational drug called SG1827, either alone or combined with other standard immunotherapy medicines, for advanced solid tumors. The goal is to see if this combination can help shrink or slow the growth of the tumor.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.